RxDoctor Payments Data

David Tyson, MD

Internal Medicine · Chicago, ILNPI 1720548100

Payments from drug & device makers

$3,880in general payments, 2019–2025

Across 193 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$520
  • Merck$318
  • EMD Serono, Inc.$157
  • Pfizer$70
  • Hologic Sales And Service, LLC$39
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$3,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,880 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$7,874
Medicare patients
17
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala90$343,337
TriumeqAbacavir/Dolutegravir/Lamivudi48$174,929
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf35$159,861
TivicayDolutegravir Sodium37$77,919
CabenuvaCabotegravir/Rilpivirine11$70,861
PrezcobixDarunavir/Cobicistat31$69,261
JulucaDolutegravir/Rilpivirine19$66,819
DelstrigoDoravirine/Lamivu/Tenofov Diso18$43,115
DovatoDolutegravir Sodium/Lamivudine14$38,955
DescovyEmtricitabine/Tenofov Alafenam13$35,323
JardianceEmpagliflozin24$12,533
JanuviaSitagliptin Phosphate19$10,332
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)24$1,625
Lurasidone Hcl11$1,338
Ventolin HfaAlbuterol Sulfate15$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Tivicay, Cabenuva, Juluca, Dovato$2,714$429,484129 claims
GileadBiktarvy, Descovy$520$378,660103 claims
MerckDelstrigo, Januvia$318$53,44737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →